Stock Research for BLUE

BLUE

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

BLUE Stock Chart & Research Data

The BLUE chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BLUE chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


BLUE Due diligence Resources & Stock Charts

The BLUE stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BLUE Detailed Price Forecast - CNN Money CNN View BLUE Detailed Summary - Google Finance
Yahoo View BLUE Detailed Summary - Yahoo! Finance Zacks View BLUE Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View BLUE Trends & Analysis - Trade-Ideas Barrons View BLUE Major Holders - Barrons
NASDAQ View BLUE Call Transcripts - NASDAQ Seeking View BLUE Breaking News & Analysis - Seeking Alpha
Spotlight View BLUE Annual Report - CompanySpotlight.com OTC Report View BLUE OTC Short Report - OTCShortReport.com
TradeKing View BLUE Fundamentals - TradeKing Charts View BLUE SEC Filings - Bar Chart
WSJ View Historical Prices for BLUE - The WSJ Morningstar View Performance/Total Return for BLUE - Morningstar
MarketWatch View the Analyst Estimates for BLUE - MarketWatch CNBC View the Earnings History for BLUE - CNBC
StockMarketWatch View the BLUE Earnings - StockMarketWatch MacroAxis View BLUE Buy or Sell Recommendations - MacroAxis
Bullish View the BLUE Bullish Patterns - American Bulls Short Pains View BLUE Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View BLUE Stock Mentions - StockTwits PennyStocks View BLUE Stock Mentions - PennyStockTweets
Twitter View BLUE Stock Mentions - Twitter Invest Hub View BLUE Investment Forum News - Investor Hub
Yahoo View BLUE Stock Mentions - Yahoo! Message Board Seeking Alpha View BLUE Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for BLUE - SECform4.com Insider Cow View Insider Transactions for BLUE - Insider Cow
CNBC View BLUE Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BLUE - OTC Markets
Yahoo View Insider Transactions for BLUE - Yahoo! Finance NASDAQ View Institutional Holdings for BLUE - NASDAQ


Stock Charts

FinViz View BLUE Stock Insight & Charts - FinViz.com StockCharts View BLUE Investment Charts - StockCharts.com
BarChart View BLUE Stock Overview & Charts - BarChart Trading View View BLUE User Generated Charts - Trading View




Latest Financial News for BLUE


bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance
Posted on Tuesday March 26, 2024

SOMERVILLE, Mass., March 26, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported fourth quarter and annual financial results and business highlights for the year ended December 31, 2023, including recent commercial and operational progress.


bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call
Posted on Monday March 25, 2024

SOMERVILLE, Mass., March 25, 2024--bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss fourth quarter and 2023 annual results and business updates on March 26, 2024, at 8:00 a.m. ET.


Why Bluebird Bio Stock Flew Higher Than the Market Today
Posted on Monday March 18, 2024

The company was thrown a financial lifeline.


bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
Posted on Monday March 18, 2024

SOMERVILLE, Mass., March 18, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced that it has entered into a $175 million five-year, term loan facility with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules"). The transaction strengthens the Company’s balance sheet as it executes on the commercial launches for its three FDA approved gene therapies – LYFGENIA for sickle cell disease, ZYNTEGLO for beta-thalassemia and SKYSONA for cerebral adrenoleukodystrophy.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.